Beyond <scp>BMI</scp> : Reassessing the Prevalence of Obesity in Patients With <scp>MASLD</scp> Under the Lancet Commission Diagnostic Criteria

AIMS: To examine obesity prevalence and reclassification under the new Lancet Commission on Obesity criteria among adults aged 18-59 years with metabolic dysfunction-associated steatotic liver disease (MASLD), including BMI-defined lean-MASLD. METHODS: for other ethnicities. RESULTS: (1) The new criteria increased the estimated prevalence of obesity among patients with MASLD from 66.8% (95% CI, 60.6%-72.4%) to 98.3% (95% CI, 97.3%-99.0%). (2) Among MASLD patients classified as non-obese by traditional criteria, 94.9% were reclassified as obese under the new criteria. (3) Among BMI-defined lean-MASLD, 84.2% met the new obesity criteria. CONCLUSION: Among adults aged 18-59 years with MASLD, the new obesity criteria increased the estimated prevalence of obesity to 98.3%. Moreover, 94.9% of individuals considered non-obese by traditional BMI criteria and 84.2% of those with BMI-defined lean MASLD met the new obesity criteria.